Surface long-tail Indian API houses with one to three active DMFs on a molecule. The qualifiable suppliers below the volume-leader top of the cohort.
Beyond the volume leaders (MSN Labs, Biophore, Dr Reddy's), the olaparib register lists 9 long-tail Indian houses with one or two active Type II DMFs and recent filing activity. BDR Lifesciences, Cdymax Pharma, and Lee Pharma sit in the qualifiable mid-tier. Several have parallel CEP coverage, marking them as serious commercial entrants rather than dossier-only houses.
| # | Supplier | Plant region | Active DMFs | Most recent filing | Inspection |
|---|---|---|---|---|---|
| 1 | BDR Lifesciences | IN · Mumbai | 1 DMF | Sep 2025 | NAI |
| 2 | Cdymax (India) Pharma | IN · Hyderabad | 1 DMF | Jun 2025 | NAI |
| 3 | Lee Pharma | IN · Hyderabad | 1 DMF | Feb 2025 | VAI |
| 4 | Alivus Life Sciences | IN · Vadodara | 1 DMF | Sep 2023 | NAI |
| 5 | Hetero Labs | IN · Hyderabad | 1 DMF | Apr 2021 | VAI |
| 6 | Cipla | IN · Goa | 1 DMF | Aug 2022 | VAI |
| 7 | Alembic Pharmaceuticals | IN · Vadodara | 1 DMF | Mar 2018 | NAI |
| 8 | Lee Fine Chem | IN · Mumbai | 1 DMF | Mar 2026 | NAI |
| 9 | Aarti Pharmalabs | IN · Mumbai | 1 DMF | Apr 2025 | VAI |
Type the INN. The AI agent pulls every Indian Type II DMF holder for that molecule from the FDA register.
Holders with one to three active DMFs on the molecule (the cohort below the volume leaders). Joined to inspection class and CEP overlap.
Citation-anchored brief with the tier-2/3 cohort, filing recency, inspection class, and a chip showing parallel CEP coverage.
Dr Reddy's, Cipla, MSN, Hetero, and the like are already named on every RFQ. The long tail surfaces the qualifiable suppliers a buyer doesn't already know.
Tier-2 houses are not all created equal. Inspection class on the row separates the qualifiable mid-tier from the speculative cohort.
A tier-2 house filing a DMF in the last 12 months is signalling active commercial intent. A 2014 vintage filing on a long-tail house is a different signal.
Long-tail houses with parallel EDQM CEPs are signalling EU-and-US ambition simultaneously. Strong candidates for trans-Atlantic supply qualification.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twenty molecules · count of Indian holders with 1-3 active DMFs (the qualifiable mid-tier).
The long tail of Indian API houses is the untapped mid-tier. PharmaDB filters the DMF cohort to the qualifiable suppliers below the volume leaders and surfaces them with inspection class, filing recency, and CEP overlap. The view rests on api_docs, legal_entities, inspections, and plant_accreditations. Refresh cadence is monthly.
PharmaDB's working definition: tier-1 are the volume leaders with 4+ active DMFs on the molecule and visible large-lane trade. Tier-2 are houses with 1-3 active DMFs and observable trade. Tier-3 are houses with active DMFs but no current trade. The long-tail page surfaces tier-2 and qualifiable tier-3.
On molecules where they hold only one active DMF, they are mid-tier for that molecule even if they are tier-1 overall. The list is molecule-specific, not company-specific.
When a long-tail Indian house holds both a Type II DMF and an EDQM CEP, the CEP shows as a chip on the row. The headline filter is FDA-DMF coverage; CEP overlap is a positive signal for trans-Atlantic supply.
A long-tail house with a 2024-or-later filing is actively positioning. A house with a 2015 vintage filing on the molecule may have shelved its commercial intent. Recency is the leading signal of which long-tail houses are realistic shortlist candidates.
Trade-validated is a strict filter on actual shipments. Long-tail is a softer filter on regulatory positioning. A house can be long-tail with no current trade (tier-3) and still be qualifiable if it has recent filings and a clean plant.
Monthly. The FDA Type II DMF register publishes monthly. Inspection class and CEP overlap refresh weekly. The catalog row carries an as-of timestamp on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.